# Shailender Bhatia

Source: https://onco.cc/people/shailender-bhatia/  
OnCo record `shailender-bhatia` (Person). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Seattle oncologist who led STAMP, the trial that showed pembrolizumab after surgery reduces recurrence of Merkel cell carcinoma, a rare and aggressive skin cancer.

## Summary

Shailender Bhatia is a medical oncologist at Fred Hutchinson Cancer Center and the University of Washington who focuses on Merkel cell carcinoma and melanoma. He was the study chair and first author of the 2025 New England Journal of Medicine report of the ECOG-ACRIN EA6174 STAMP trial, in which adjuvant pembrolizumab improved recurrence-free survival compared with observation after resection of stage I to III Merkel cell carcinoma.

## Fields

- Kind: Person
- Last checked: 2026-09-18
- Tags: skin; immunotherapy; trialist
- Role: Medical oncologist, Fred Hutchinson Cancer Center and University of Washington
- Specialisms: Merkel cell carcinoma; Melanoma; Immunotherapy

## Connected records

- cancers: [Melanoma](https://onco.cc/cancers/melanoma/), [Merkel cell carcinoma](https://onco.cc/cancers/merkel-cell-carcinoma/), [Skin cancer (all types)](https://onco.cc/cancers/skin-cancer/)
- institutions: [Fred Hutchinson Cancer Center](https://onco.cc/institutions/fred-hutch/)
- trials: [STAMP (EA6174)](https://onco.cc/trials/stamp-merkel/)

---
JSON: https://onco.cc/api/v1/entities/shailender-bhatia.json